

Table 19.29  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2009-2015

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	
Lymphoid Neoplasm	184,989	71.3 ( 71.0 , 71.6 )	90.5 ( 89.8 , 91.2 )	78.6 ( 78.3 , 78.9 )	61.7 ( 61.2 , 62.2 )			
1 Hodgkin Lymphoma	14,589	86.6 ( 85.9 , 87.3 )	97.3 ( 96.2 , 98.0 )	90.0 ( 89.3 , 90.7 )	58.0 ( 55.0 , 60.9 )			
2 Non-Hodgkin lymphoma	166,396	70.4 ( 70.1 , 70.7 )	88.8 ( 88.0 , 89.6 )	77.2 ( 76.8 , 77.5 )	62.4 ( 61.9 , 62.9 )			
2(a) Non-Hodgkin lymphoma, B-cell	154,493	70.7 ( 70.4 , 71.1 )	89.6 ( 88.7 , 90.4 )	77.9 ( 77.5 , 78.3 )	62.9 ( 62.4 , 63.4 )			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	8,624	68.9 ( 67.7 , 70.0 )	88.9 ( 87.9 , 89.9 )	41.9 ( 39.6 , 44.2 )	17.8 ( 14.2 , 21.8 )			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	137,350	71.0 ( 70.7 , 71.4 )	92.5 ( 90.6 , 94.0 )	79.3 ( 78.9 , 79.7 )	63.4 ( 62.9 , 64.0 )			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	33,231	81.6 ( 80.8 , 82.3 )	93.8 ( 63.0 , 99.1 )	88.9 ( 88.1 , 89.6 )	76.5 ( 75.4 , 77.5 )			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	29,025	84.5 ( 83.8 , 85.3 )	91.7 ( 53.7 , 98.8 )	91.8 ( 91.0 , 92.6 )	79.6 ( 78.4 , 80.7 )			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	90	53.7 ( 39.8 , 65.8 )	100.0 ( - , - )	63.9 ( 40.2 , 80.3 )	43.4 ( 26.0 , 59.7 )			
2(a) 2.1.3. Mantle-cell lymphoma	4,116	61.1 ( 59.0 , 63.2 )	- ( - , - )	70.2 ( 67.4 , 72.8 )	54.0 ( 50.9 , 57.0 )			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	3,069	82.8 ( 80.3 , 85.1 )	100.0 ( - , - )	89.6 ( 86.6 , 91.9 )	78.9 ( 75.2 , 82.1 )			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	1,363	82.2 ( 78.3 , 85.4 )	100.0 ( - , - )	85.9 ( 81.2 , 89.6 )	79.8 ( 74.2 , 84.3 )			
2(a) 2.2.2. Waldenstrom macroglobulinemia	1,706	83.4 ( 79.8 , 86.3 )	- ( - , - )	92.5 ( 88.3 , 95.2 )	78.2 ( 73.1 , 82.5 )			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	35,369	63.2 ( 62.6 , 63.9 )	90.8 ( 87.4 , 93.2 )	72.8 ( 72.0 , 73.6 )	53.7 ( 52.6 , 54.7 )			
2(a) 2.3.1. DLBCL, NOS <sup>c</sup>	34,815	62.9 ( 62.3 , 63.6 )	90.8 ( 87.3 , 93.4 )	72.5 ( 71.7 , 73.3 )	53.7 ( 52.6 , 54.7 )			
2(a) 2.3.2. Intravascular large B-cell lymphoma	69	47.8 ( 34.1 , 60.3 )	- ( - , - )	52.6 ( 34.1 , 68.2 )	42.6 ( 23.2 , 60.8 )			
2(a) 2.3.3. Primary effusion lymphoma	47	52.4 ( 35.7 , 66.7 )	- ( - , - )	50.6 ( 32.1 , 66.5 )	54.2 ( 18.3 , 80.2 )			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	438	88.4 ( 84.5 , 91.4 )	89.9 ( 71.7 , 96.7 )	90.3 ( 86.3 , 93.2 )	47.9 ( 24.1 , 68.3 )			
2(a) 2.4. Burkitt lymphoma/leukemia	2,170	64.1 ( 61.8 , 66.3 )	92.8 ( 89.8 , 95.0 )	59.8 ( 56.7 , 62.7 )	38.9 ( 33.3 , 44.5 )			
2(a) 2.5. Marginal-zone lymphoma (MZL)	10,080	90.3 ( 89.2 , 91.3 )	98.6 ( 90.6 , 99.8 )	94.2 ( 93.1 , 95.1 )	86.4 ( 84.4 , 88.2 )			
2(a) 2.5.1. Splenic MZL	850	87.2 ( 82.8 , 90.6 )	- ( - , - )	90.0 ( 85.0 , 93.5 )	85.2 ( 77.8 , 90.2 )			
2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type	6,278	93.9 ( 92.5 , 95.0 )	98.0 ( 86.3 , 99.7 )	95.9 ( 94.6 , 96.9 )	91.4 ( 88.7 , 93.5 )			
2(a) 2.5.3. Nodal MZL	2,952	83.6 ( 81.3 , 85.7 )	100.0 ( - , - )	91.0 ( 88.5 , 92.9 )	77.4 ( 73.5 , 80.7 )			
2(a) 2.6. Follicular lymphoma	17,590	88.4 ( 87.6 , 89.2 )	95.5 ( 82.0 , 98.9 )	92.9 ( 92.1 , 93.6 )	82.6 ( 81.0 , 84.1 )			
2(a) 2.7. Hairy-cell leukemia	1,569	94.2 ( 91.7 , 95.9 )	- ( - , - )	97.0 ( 95.7 , 97.9 )	85.6 ( 78.6 , 90.4 )			
2(a) 2.8. Plasma cell neoplasms	34,254	52.2 ( 51.4 , 52.9 )	83.6 ( 48.8 , 95.6 )	63.5 ( 62.5 , 64.5 )	43.5 ( 42.5 , 44.5 )			
2(a) 2.8.1. Plasmacytoma	2,009	70.7 ( 67.8 , 73.4 )	90.0 ( 47.3 , 98.5 )	79.7 ( 76.3 , 82.6 )	59.0 ( 53.9 , 63.7 )			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	32,245	51.0 ( 50.2 , 51.8 )	50.0 ( 0.6 , 91.0 )	62.2 ( 61.1 , 63.2 )	42.8 ( 41.7 , 43.8 )			
2(a) 2.9. Heavy chain disease	18	61.4 ( 28.3 , 82.8 )	100.0 ( - , - )	83.9 ( 12.0 , 98.6 )	29.5 ( 3.6 , 63.8 )			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>	8,519	68.4 ( 66.9 , 69.8 )	91.7 ( 79.4 , 96.8 )	78.4 ( 76.6 , 80.2 )	61.9 ( 59.8 , 64.0 )			

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.29 - continued  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2009-2015

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	
2(b) Non-Hodgkin lymphoma, T-cell	11,325	66.1 ( 65.0 , 67.2 )	85.6 ( 83.3 , 87.6 )	70.2 ( 68.9 , 71.6 )	52.2 ( 50.0 , 54.4 )			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	187	65.2 ( 57.6 , 71.8 )	91.7 ( 83.3 , 96.0 )	48.4 ( 36.6 , 59.2 )	- ( - , - )			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	11,122	66.2 ( 65.0 , 67.2 )	85.1 ( 82.6 , 87.2 )	70.6 ( 69.3 , 71.9 )	52.4 ( 50.1 , 54.6 )			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	2,846	90.9 ( 88.9 , 92.6 )	100.0 ( - , - )	93.1 ( 91.1 , 94.6 )	85.8 ( 80.8 , 89.6 )			
2(b) 2.1.1. Mycosis fungoides	2,746	92.4 ( 90.5 , 94.0 )	100.0 ( - , - )	94.1 ( 92.2 , 95.6 )	88.2 ( 83.0 , 91.9 )			
2(b) 2.1.2. Sezary syndrome	100	45.4 ( 31.2 , 58.5 )	- ( - , - )	46.3 ( 26.5 , 64.0 )	45.7 ( 26.9 , 62.8 )			
2(b) 2.2. Peripheral T-cell lymphoma	5,920	58.4 ( 56.9 , 60.0 )	86.9 ( 81.9 , 90.6 )	66.5 ( 64.6 , 68.4 )	44.1 ( 41.3 , 46.7 )			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>	2,119	40.0 ( 37.5 , 42.5 )	64.2 ( 46.6 , 77.3 )	49.9 ( 46.6 , 53.2 )	27.4 ( 23.8 , 31.2 )			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	780	38.6 ( 34.4 , 42.8 )	100.0 ( - , - )	48.4 ( 41.9 , 54.6 )	31.1 ( 25.6 , 36.9 )			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	88	90.3 ( 78.4 , 95.8 )	88.4 ( 40.6 , 98.3 )	88.0 ( 72.9 , 95.0 )	93.7 ( 32.0 , 99.6 )			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	1,110	67.6 ( 64.3 , 70.7 )	89.6 ( 83.2 , 93.6 )	71.6 ( 67.7 , 75.2 )	45.6 ( 37.7 , 53.1 )			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	66	32.7 ( 20.0 , 45.9 )	66.8 ( 5.3 , 94.6 )	31.0 ( 17.4 , 45.6 )	- ( - , - )			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	69	9.3 ( 3.3 , 19.3 )	- ( - , - )	10.9 ( 2.8 , 25.4 )	7.5 ( 1.4 , 21.0 )			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>	1,183	84.7 ( 81.3 , 87.5 )	100.0 ( - , - )	88.8 ( 85.3 , 91.5 )	77.1 ( 69.6 , 82.9 )			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	505	88.1 ( 82.7 , 91.9 )	91.3 ( 69.3 , 97.8 )	91.8 ( 86.5 , 95.1 )	81.2 ( 68.5 , 89.2 )			
2(b) 2.3. Adult T-cell leukemia/lymphoma	1,671	64.1 ( 61.3 , 66.7 )	83.2 ( 80.0 , 85.9 )	49.6 ( 45.0 , 54.0 )	21.6 ( 13.8 , 30.4 )			
2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia	466	42.7 ( 37.3 , 47.9 )	58.8 ( 32.5 , 77.8 )	44.4 ( 38.2 , 50.4 )	35.7 ( 24.7 , 46.8 )			
2(b) 2.5. T-cell large granular lymphocytic leukemia	28	63.8 ( 38.7 , 80.8 )	- ( - , - )	78.5 ( 43.7 , 93.1 )	46.0 ( 14.7 , 73.1 )			
2(b) 2.6. Prolymphocytic leukemia, T-cell	191	14.7 ( 8.8 , 22.0 )	- ( - , - )	23.0 ( 13.4 , 34.2 )	5.0 ( 1.0 , 14.4 )			
2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell	16	44.3 ( 16.7 , 69.0 )	- ( - , - )	38.8 ( 10.3 , 67.3 )	41.4 ( 5.1 , 77.0 )			
2(c) Non-Hodgkin lymphoma, unknown lineage	578	52.9 ( 48.2 , 57.4 )	84.6 ( 74.3 , 91.0 )	52.9 ( 46.1 , 59.1 )	41.6 ( 33.6 , 49.3 )			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	194	59.3 ( 51.7 , 66.2 )	85.5 ( 75.1 , 91.7 )	52.8 ( 39.2 , 64.7 )	23.9 ( 12.3 , 37.6 )			
2(c) 2. Prolymphocytic leukemia, unknown lineage	19	38.4 ( 15.5 , 61.2 )	- ( - , - )	- ( - , - )	29.9 ( 8.9 , 54.7 )			
2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage	365	50.0 ( 43.7 , 55.9 )	50.0 ( 0.6 , 91.0 )	52.5 ( 44.6 , 59.8 )	47.0 ( 37.1 , 56.3 )			
2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>	9,005	68.6 ( 67.5 , 69.7 )	88.9 ( 87.9 , 89.9 )	42.6 ( 40.3 , 44.8 )	18.3 ( 14.8 , 22.0 )			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	290	77.3 ( 70.4 , 82.8 )	- ( - , - )	83.9 ( 76.3 , 89.2 )	65.7 ( 51.3 , 76.8 )			
4 Lymphoid neoplasm, NOS <sup>c</sup>	3,714	51.7 ( 49.6 , 53.7 )	84.7 ( 76.3 , 90.4 )	66.9 ( 64.0 , 69.5 )	40.0 ( 37.2 , 42.8 )			

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.